本文選題：帕拉米韋 + 流感　； 參考：《中國新藥雜志》2017年08期

【摘要】：目的:為帕拉米韋的臨床合理應(yīng)用提供參考。方法:收集國外關(guān)于帕拉米韋用于治療流感病毒的臨床有效性和安全性研究文獻,進行歸納和綜述。結(jié)果:共檢索到303篇文獻記錄,最終篩選出10篇文獻。研究結(jié)果顯示:帕拉米韋對健康受試者具有良好的安全性和耐受性;帕拉米韋治療無并發(fā)癥的住院流感患者疾病持續(xù)時間為38.7 h(400 mg組)和45.5 h(200 mg組),治療感染流感病毒的高�；颊呔徑饬鞲邪Y狀的平均時間為68.6 h;治療季節(jié)性甲型H3N2流感,帕拉米韋組患者體溫下降至37.5℃以下所用的時間最短(均值17.0 h);對老人、兒童、孕婦以及患有基礎(chǔ)疾病的流感患者,帕拉米韋的療效與其他神經(jīng)氨酸酶抑制劑相比更顯著。結(jié)論:帕拉米韋的耐受性好,不易出現(xiàn)耐藥,且安全性較好,是目前極具應(yīng)用價值的抗流感新藥。
[Abstract]:Objective: to provide reference for rational clinical application of paramivir. Methods: the literature on the clinical efficacy and safety of paramivir in the treatment of influenza virus was collected and summarized. Results: a total of 303 literature records were retrieved and 10 articles were screened out. The results showed that paramivir had good safety and tolerance to healthy subjects. The duration of inpatients with influenza without complications was 38.7 h (400 mg group) and 45.5 h (200 mg group), and the average time of relieving influenza symptoms in high-risk patients infected with influenza virus was 68.6 h. The effect of paramivir on the elderly, children, pregnant women and influenza patients with underlying diseases was significantly higher than that of other neuraminidase inhibitors in the paramivir group, which took the shortest time to fall below 37. 5 鈩，

本文編號：2104112